-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.
-
- Our Pipeline Development
-
Nu.Q® Cancer
We are developing a range of blood-based assays with potential applications beyond cancer detection.
-
Capture-Seq™
We have developed Capture-Seq™, a novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples.
ELCC 2026: Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation
- Share
- Tweet
- Share on Facebook
- Share
Poster titled: Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation
Pei-Hsing Chen, Chia-Wei Weng, Tai-Horng Young, Tzu-Pin Lu, D. Pamart, A. Kotronoulas, M. Herzog, J. Micallef, Hsao-Hsun Hsu, Jin-Shing Chen
Presented at ELCC 2026
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields